Evidence for an enzymatic defect in the 4‐hydroxylation of debrisoquine by human liver.
Authors:
- Ds DaviesDDDs Davies
- Gc KahnGKGc Kahn
- S MurraySMS Murray
- Mj BrodieMBMj Brodie
- Ar BoobisABAr Boobis
Open Access
- 1 January 1981
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 11 (1) , 89-91
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Deficient metabolism of debrisoquine and sparteineClinical Pharmacology & Therapeutics, 1980
- Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquineEuropean Journal of Clinical Pharmacology, 1980
- Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.British Journal of Clinical Pharmacology, 1980
- Toxicological Implications of Polymorphic Drug Metabolism1980
- Biphasic Michaelis-Menten kinetics for ethoxycoumarin and phenacetin metabolism by human and rat hepatic monooxygenases [proceedings].1979
- Polymorphism of carbon oxidation of drugs and clinical implications.BMJ, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1977
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Determination of debrisoquin and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometryAnalytical Chemistry, 1976
- GUANETHIDINE AND RELATED AGENTS. II. METABOLISM BY HEPATIC MICROSOMES AND ITS INHIBITION BY DRUGSThe Journal of Pharmacology and Experimental Therapeutics, 1970